OMER
OMEROS CORP
NASDAQ · Healthcare · Biotechnology · US
$17.87
−3.14%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$18.69
From 52W high−7.84%
Volume2.14M
Market cap$1.29B
P/E (TTM)9.4x
P/S (TTM)33.7x
Div yield—
Key dataSep 18, 2026
Open
$18.69
From 52W high
−7.84%
Volume
2.14M
Market cap
$1.29B
ValuationView details →
P/E (Fwd)
8.0x
EV/EBITDA
9.1x
P/E (TTM)
9.4x
RSI (14)
55.5
MomentumView details →
1D Return
−3.14%
YTD Return
+5.09%
SummaryUpdated Jun 1, 2026
Omeros Corporation (NASDAQ:OMER) is a commercial-stage biopharmaceutical company founded in 1994 and headquartered in Seattle, Washington. The company went public in 2009 and focuses on discovering, developing, and commercializing innovative therapeutics for rare diseases, particularly those involving complement-mediated disorders, inflammatory conditions, and addictive behaviors. Omeros has evolved from a research-stage company to having one commercialized product generating royalty revenue, while advancing multiple late-stage clinical programs targeting significant unmet medical needs in orphan disease markets.
Similar companies
Latest newsMore news →
Omeros reduced its convertible debt after the quarter ended.39d agoOmeros reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for TA-TMA, and generated positive operating cash flow.39d agoOmeros Corporation appointed Joseph Schocken as a director, effective August 12, 2026, and granted him a stock option to purchase 30,000 shares of common stock on the date of appointment.39d ago